Xilio Therapeutics Inc

NASDAQ:XLO   12:08:19 PM EDT
13.64
-0.67 (-4.68%)
Regulatory, Earnings Announcements

Xilio Therapeutics Reports Pipeline And Business Progress And Third Quarter 2021 Financial Results

Published: 12/02/2021 13:09 GMT
Xilio Therapeutics Inc (XLO) - Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results.
Xilio Therapeutics Inc - Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for Xtx202, a Tumor-selective Il-2, in Q1 of 2022.
Xilio Therapeutics Inc- Submission of an Ind for Xtx301 in Second Half of 2022.
Xilio Therapeutics Inc - Existing Cash, Cash Equivalents, Ipo Proceeds Will Enable Co to Fund Operating Expenses and Capital Expenditure Into 2024.
Xilio Therapeutics Inc - Qtrly Net Loss per Share $21.27.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.11

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.84

More details on our Analysts Page.